Physician profile
Dean Currie
NPI 1356346142
$2,305.00
in general payments reported to CMS, 2019-2025
29 companies · $97.26 in 2025
The $97.26 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $549 · 2020: $47.93 · 2021: $215 · 2022: $529 · 2023: $333 · 2024: $535 · 2025: $97.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $964.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $299.06 | 2020-2022 | |
| Edwards Lifesciences Corporation | $235.63 | 2022-2023 | Hemosphere |
| Hologic Sales and Service, LLC | $224.06 | 2024 | Localizer, Trunode, Celero-12 |
| Portola Pharmaceuticals, LLC | $209.64 | 2019-2020 | |
| Abbvie INC. | $207.49 | 2023-2025 | Strattice Reconstructive Tissue Matrix Bps |
| Lemaitre Vascular, INC. | $128.46 | 2019-2024 | Artegraft Vascular Graft |
| Alexion Pharmaceuticals, INC. | $116.09 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $107.93 | 2019-2025 | Exparel |
| Astrazeneca Pharmaceuticals LP | $102.21 | 2023-2024 | Andexxa |
| Ethicon US, LLC | $71.87 | 2019 | |
| Tela Bio, INC. | $66.67 | 2023-2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex), Ovitex 2s |
| Medtronic, INC. | $63.12 | 2022-2024 | Truclear |
| Merit Medical Systems INC | $44.54 | 2022-2025 | Savi Scout |
| Merck Sharp & Dohme LLC | $41.17 | 2021-2023 | Lynparza, Keytruda |
| Silk Road Medical, INC. | $40.66 | 2019-2023 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conmed Corporation | $39.87 | 2019 | |
| Shire North American Group INC | $38.46 | 2019 | |
| Myriad Genetic Laboratories, INC. | $36.11 | 2023-2025 | Myrisk |
| Boston Scientific Corporation | $34.59 | 2019-2023 | Spyglass |
| Elucent Medical | $31.56 | 2022 | |
| W. L. Gore & Associates, INC. | $24.50 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.70 | 2021 | |
| Cook Medical LLC | $19.50 | 2023 | Zilver Ptx |
| Tactile Systems Technology INC | $19.45 | 2021 | |
| Endogastric Solutions, INC | $18.80 | 2022 | |
| Smith+Nephew, INC. | $17.03 | 2024 | Renasys |
| Z-Medica, LLC | $16.53 | 2020 | |
| Hologic INC | $15.21 | 2019 | |
| Teleflex LLC | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dean Currie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.